Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A Roadblock to Personalized Cancer Care

Published: Tuesday, August 06, 2013
Last Updated: Tuesday, August 06, 2013
Bookmark and Share
Experts call for more support for tumor biomarker tests; fixing a vicious cycle will lead to tests that better predict treatment success.

There’s a major roadblock to creating personalized cancer care.

Doctors need a way to target treatments to patients most likely to benefit and avoid treating those who will not. Tumor biomarker tests can help do this.

The problem, according to a new commentary paper, is that, unlike drugs or other therapies, cancer biomarker tests are undervalued by doctors and patients. The authors say that inconsistent regulatory rules, inadequate payment and underfunded tumor biomarker research has left us in a vicious cycle that prevents development and testing of reliable biomarker tests that could be used to personalize clinical care of patients with cancer.

“Right now biomarkers are not valued nearly to the extent that we see with therapeutics. But if a tumor biomarker test is being used to decide whether a patient should receive a certain treatment, then it is as critical for patient care as a therapeutic agent. A bad test is as dangerous as a bad drug,” says Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.

Hayes led a blue-ribbon panel of experts from universities, corporations, insurance and advocacy organizations to outline the issues in a commentary published today in Science Translational Medicine.

Tumor biomarker tests look at the genetic or molecular make-up of a tumor to determine whether the cancer is likely to progress, and if so, if it is likely to respond to treatment. If the test is good, it can help doctors decide when a patient can safely skip further therapy, or it can be used to direct which drug might be most likely to help. The result: “personalized medicine,” which means patients get treatments that benefit them specifically and they avoid treatments – including their costs and side effects – that are not likely to make a difference for them.

The regulatory process, the research funding, the reimbursement, even the standards for journal publications for tumor biomarker tests are all meager compared to the robust support for drug development, the authors say.

This creates a vicious cycle in which researchers and drug companies don’t invest in tumor biomarker research, tests are not fully evaluated in clinical trials, and tests with uncertain value in terms of predicting the success of treatment are published. This in turn means that few of these tests are included in evidence-based care guidelines, leaving health care professionals unsure of whether or how to use the test, and third-party payers unsure of how much to pay for them.

The authors outline five recommendations and suggest that all five must be addressed to break the vicious cycle:

1.    Reform regulatory review of tumor biomarker tests
2.    Increase reimbursement for tumor biomarker tests that are proven to help determine which therapies will or are working
3.    Increase investment for tumor biomarker research so it’s comparable to new drug research
4.    Increase the rigor for peer review of tumor biomarker publications
5.    Include only proven biomarker tests in evidence-based care guidelines

“These recommendations are not about creating more regulation; they are about creating an even playing field that allows tumor biomarker tests to be developed and proven clinically relevant. We want to stimulate innovation yet hold investigators and clinicians to the highest scientific standards – as we now do for therapeutics,” Hayes says. “We need to change the way we value tumor biomarkers in this country.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New Factor in Depression?
Study in humans & rats shows more physical changes in depressed brains.
Thursday, September 10, 2015
Scientists Slow Development of Alzheimer's Cell-Killing Plaques
Researchers have learned how to fix a cellular structure called the Golgi that becomes fragmented in Alzheimer's patients.
Tuesday, March 18, 2014
Promising new Target Emerges for Autoimmune Diseases
Michigan scientists have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body’s own cells.
Thursday, September 03, 2009
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections
New study uncovers significant proportion of potential false negatives in widely used HPV DNA test which could lead to cervical cancer.
Tuesday, July 21, 2009
University of Michigan' Researcher Provides Model of Cell's Messengers
Study provides molecular view of how the G proteins can be arranged at the cell membrane.
Friday, December 16, 2005
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Disordered Protein 'Shape Shifts' to Avoid Crowding
Study suggests disordered protein escapes from the cell membrane when it runs out of space.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Cancer's Taste for Fat
Researchers discovered signalling pathway for fat burning is disrupted in certain cancers.
Space Research Fighting Cancer
JPL and National Cancer Institute renew Big Data partnership that 'learns' data similarities.
"Pac-man Protein" May Aid the Fight Against Cancer
Scientists at the University of Sheffield have identified a protein which causes cells to eat their dying neighbours, helping to prevent inflammation – something which is vital in the fight to stop cancer spreading.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!